PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/NCE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in allergy and dermatology discuss advances in the management of allergic and inflammatory diseases presented at the 2019 American Academy of Dermatology Annual Meeting and the American Academy of Allergy, Asthma & Immunology 2019 Annual Meeting. Upon completion of this activity, participants will be able to: Describe the relationship between type 2 inflammatory disorders, including atopic dermatitis, asthma, chronic rhinosinusitis and nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE), Discuss emerging data related to the efficacy and safety of therapies for the treatment of allergic and inflammatory diseases, Apply the latest clinical data to the treatment of patients with allergic and inflammatory disorders, such as atopic dermatitis, asthma, CRS/NP, and EoE.

Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.

Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they’re used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.

Go online to PeerView.com/XYB860 to view the entire program with slides. In this activity, an expert in the management of Lennox-Gastaut syndrome discusses the challenges of identifying, diagnosing, and treating patients with this condition. Upon completion of this activity, participants should be better able to: Identify patients with Lennox-Gastaut syndrome based on the presence of cardinal symptoms and hallmark features, Cite current data on approved pharmacologic therapies for the treatment of seizures associated with Lennox-Gastaut syndrome, Develop personalized seizure management regimens for patients with Lennox-Gastaut syndrome.

Go online to PeerView.com/QYB860 to view the entire program with slides. In this activity, which is based on recent live meetings held in Baltimore and Cambridge, Maryland, clinicians practicing on the front-lines of the intersecting hepatitis C and opioid epidemics offer thought-provoking perspectives on identifying HCV among people with substance use disorders who live in urban and rural healthcare settings and successfully engaging them in care to achieve better patient and community outcomes. Upon completion of this activity, participants will be able to: Evaluate patients with, or at risk of, hepatitis C virus (HCV) infection in order to make appropriate referrals for screening, diagnosis, treatment, or follow-up, Apply evidence-based strategies for supporting patients with injection drug use in harm reduction and adhering to potential HCV treatment and monitoring regimens, Integrate patient-centered HCV education into substance abuse/addiction center visits and programs, Collaborate with addiction professionals, social workers, case managers, primary care providers, infectious disease physicians, and HCV specialists to facilitate an interdisciplinary approach to HCV care and treatment for people who inject drugs (PWID)

Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

Addressing Unmet Needs in Scalp Psoriasis: A Closer Look at Current Management Strategies and the Clinical Potential of New Therapeutic Options

Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer’s Disease: What Are the Implications for Treatment?

The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond